shutterstock_1953872293_marlon_trottmann

Marlon Trottmann / Shutterstock.com

13 December 2022AmericasStaff Writer

Amgen seals $28m deal for biotech

Two rivals withdrew from acquisition process | Agreement provides access to blockbuster medicines | Janssen Global Services | Sanofi.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Amgen continues M&A flurry with $3.7bn deal

8 August 2022 Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics / Deal includes acquisition of Tavneos / Spate of acquisitions follows increased competition.

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

More on this story

Amgen continues M&A flurry with $3.7bn deal

8 August 2022 Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics / Deal includes acquisition of Tavneos / Spate of acquisitions follows increased competition.

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

More on this story

Amgen continues M&A flurry with $3.7bn deal

8 August 2022 Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics / Deal includes acquisition of Tavneos / Spate of acquisitions follows increased competition.

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

More features

President Trump 2.0: Five major areas to watch

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug